drugset / Trial / NCT05188729
Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma
Phase 2
Completed
92 enrolled
Verrica Pharmaceuticals Inc.
Canfield Scientific Inc. · collabHeartcoR Solutions · collabInstat Clinical Research · collabMyonex · collabOncoBay Clinical · collabQ2 Solutions · collabVeristat, Inc. · collabVial Health Technology, Inc · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a 2-part, open-label, multicenter, dose-escalation, proof-of-concept study with a safety run-in designed to assess the safety, tolerability, MTD, and objective antitumor efficacy of ascending dose strengths of VP-315 when administered intratumorally to adults with biopsy proven basal cell carcinoma (BCC). The study is expected to enroll approximately 86 subjects with a histological diagnosis of BCC in at least 1 eligible target lesion (confirmed by punch or shave biopsy).
Timeline
- Start
- 2022-02-01
- Primary completion
- 2024-04-15
- Completion
- 2024-04-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VP-315 | Unknown | 2 mg | Other |
| Subject | VP-315 | Unknown | 3 mg | Other |
| Subject | VP-315 | Unknown | 4 mg | Other |
| Subject | VP-315 | Unknown | 5 mg | Other |
| Subject | VP-315 | Unknown | 6 mg | Other |
| Subject | VP-315 | Unknown | 7 mg | Other |
| Subject | VP-315 | Unknown | 8 mg | Other |